204 related articles for article (PubMed ID: 32122369)
21. Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV.
Joyce VR; Sun H; Barnett PG; Bansback N; Griffin SC; Bayoumi AM; Anis AH; Sculpher M; Cameron W; Brown ST; Holodniy M; Owens DK
MDM Policy Pract; 2017; 2(2):2381468317716440. PubMed ID: 30288427
[No Abstract] [Full Text] [Related]
22. VALIDATION AND COMPARISON OF EQ-5D-3L AND SF-6D INSTRUMENTS IN A SPANISH PARKINSON´S DISEASE POPULATION SAMPLE.
Garcia-Gordillo MÁ; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellan-Perpiñan JM; Sanchez-Martinez FI
Nutr Hosp; 2015 Dec; 32(6):2808-21. PubMed ID: 26667738
[TBL] [Abstract][Full Text] [Related]
23. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease.
Santos-García D; de la Fuente-Fernández R
J Neurol Sci; 2013 Sep; 332(1-2):136-40. PubMed ID: 23890935
[TBL] [Abstract][Full Text] [Related]
24. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
[TBL] [Abstract][Full Text] [Related]
25. Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping.
Gray LA; Wailoo AJ; Hernandez Alava M
Value Health; 2018 Dec; 21(12):1399-1405. PubMed ID: 30502783
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications.
Dams J; Balzer-Geldsetzer M; Siebert U; Deuschl G; Schuepbach WM; Krack P; Timmermann L; Schnitzler A; Reese JP; Dodel R;
Mov Disord; 2016 Aug; 31(8):1183-91. PubMed ID: 27506638
[TBL] [Abstract][Full Text] [Related]
27. Prediction of depression and anxiety via patient-assessed tremor severity, not physician-reported motor symptom severity, in patients with Parkinson's disease or essential tremor who have undergone deep brain stimulation.
Achey RL; Yamamoto E; Sexton D; Hammer C; Lee BS; Butler RS; Thompson NR; Nagel SJ; Machado AG; Lobel DA
J Neurosurg; 2018 Dec; 129(6):1562-1571. PubMed ID: 29473781
[TBL] [Abstract][Full Text] [Related]
28. The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease.
Schrag A; Selai C; Jahanshahi M; Quinn NP
J Neurol Neurosurg Psychiatry; 2000 Jul; 69(1):67-73. PubMed ID: 10864606
[TBL] [Abstract][Full Text] [Related]
29. Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease.
Dams J; Klotsche J; Bornschein B; Reese JP; Balzer-Geldsetzer M; Winter Y; Schrag A; Siderowf A; Oertel WH; Deuschl G; Siebert U; Dodel R
Health Qual Life Outcomes; 2013 Mar; 11():35. PubMed ID: 23497005
[TBL] [Abstract][Full Text] [Related]
30. Quality of life in a German cohort of Parkinson's patients assessed with three different measures.
Balzer-Geldsetzer M; Klotsche J; ; Dodel R; Riedel O
J Neurol; 2018 Nov; 265(11):2713-2722. PubMed ID: 30209651
[TBL] [Abstract][Full Text] [Related]
31. Quality of life outcomes following cervical decompression for coexisting Parkinson's disease and cervical spondylotic myelopathy.
Xiao R; Miller JA; Lubelski D; Alberts JL; Mroz TE; Benzel EC; Krishnaney AA; Machado AG
Spine J; 2016 Nov; 16(11):1358-1366. PubMed ID: 27496286
[TBL] [Abstract][Full Text] [Related]
32. Beneficial effects of bilateral subthalamic stimulation on alexithymia in Parkinson's disease.
Dafsari HS; Ray-Chaudhuri K; Mahlstedt P; Sachse L; Steffen JK; Petry-Schmelzer JN; Dembek TA; Reker P; Barbe MT; Visser-Vandewalle V; Fink GR; Timmermann L
Eur J Neurol; 2019 Feb; 26(2):222-e17. PubMed ID: 30107062
[TBL] [Abstract][Full Text] [Related]
33. Quality of life predicts outcome of deep brain stimulation in early Parkinson disease.
Schuepbach WMM; Tonder L; Schnitzler A; Krack P; Rau J; Hartmann A; Hälbig TD; Pineau F; Falk A; Paschen L; Paschen S; Volkmann J; Dafsari HS; Barbe MT; Fink GR; Kühn A; Kupsch A; Schneider GH; Seigneuret E; Fraix V; Kistner A; Chaynes PP; Ory-Magne F; Brefel-Courbon C; Vesper J; Wojtecki L; Derrey S; Maltête D; Damier P; Derkinderen P; Sixel-Döring F; Trenkwalder C; Gharabaghi A; Wächter T; Weiss D; Pinsker MO; Regis JM; Witjas T; Thobois S; Mertens P; Knudsen K; Schade-Brittinger C; Houeto JL; Agid Y; Vidailhet M; Timmermann L; Deuschl G;
Neurology; 2019 Mar; 92(10):e1109-e1120. PubMed ID: 30737338
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal predictive ability of mapping models: examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients.
Kontodimopoulos N; Bozios P; Yfantopoulos J; Niakas D
Eur J Health Econ; 2013 Apr; 14(2):307-14. PubMed ID: 22252308
[TBL] [Abstract][Full Text] [Related]
35. Neuropsychological changes following deep brain stimulation surgery for Parkinson's disease: comparisons of treatment at pallidal and subthalamic targets versus best medical therapy.
Rothlind JC; York MK; Carlson K; Luo P; Marks WJ; Weaver FM; Stern M; Follett K; Reda D;
J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):622-9. PubMed ID: 25185211
[TBL] [Abstract][Full Text] [Related]
36. Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms.
Woodcock F; Doble B;
Med Decis Making; 2018 Nov; 38(8):954-967. PubMed ID: 30226101
[TBL] [Abstract][Full Text] [Related]
37. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
Pickard AS; Gooderham M; Hartz S; Nicolay C
J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
[TBL] [Abstract][Full Text] [Related]
38. Obtaining EQ-5D-3L utility index from the health status scale of traditional Chinese medicine (TCM-HSS) based on a mapping study.
Wang L; Lu Y; Dai Z; Shi P; Xu J; Chang F; Lu Y
Health Qual Life Outcomes; 2022 Dec; 20(1):164. PubMed ID: 36522665
[TBL] [Abstract][Full Text] [Related]
39. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
40. Are condition-specific utilities more valid than generic preference-based ones in asthma? Evidence from a study comparing EQ-5D-3L and SF-6D with AQL-5D.
Kontodimopoulos N; Stamatopoulou E; Brinia A; Talias MA; Ferreira LN
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):667-675. PubMed ID: 30048194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
